Sexual dysfunction during treatment of major depressive disorder with vilazodone, citalopram, or placebo: results from a phase IV clinical trial

Anita H Clayton, Carl Gommoll, Dalei Chen, Rene Nunez, Maju Mathews, Anita H Clayton, Carl Gommoll, Dalei Chen, Rene Nunez, Maju Mathews

Abstract

Sexual dysfunction commonly occurs with major depressive disorder (MDD). Vilazodone, a selective serotonin reuptake inhibitor and 5-HT1A receptor partial agonist antidepressant approved for the treatment of MDD in adults, was evaluated to determine its effects on sexual function. The primary study was a double-blind, randomized, controlled trial comparing vilazodone 20 and 40 mg/day with placebo; citalopram 40 mg/day was an active control (NCT01473381; http://www.clinicaltrials.gov). Post-hoc analyses evaluated change from baseline to week 10 on the Changes in Sexual Functioning Questionnaire (CSFQ); no inferential statistics were performed. CSFQ scores increased for women [1.2 (citalopram) to 3.0 (vilazodone 40 mg)] and men [1.2 (vilazodone 40 mg) to 3.5 (placebo)] in all treatment groups. Greater changes in CSFQ scores were seen in responders [women: 2.33 (citalopram) to 5.06 (vilazodone 40 mg); men: 2.26 (vilazodone 40 mg) to 4.35 (placebo)] versus nonresponders. CSFQ change from baseline was small for patients with normal baseline sexual function; in patients with baseline sexual dysfunction, CSFQ scores improved across groups [women: 2.35 (citalopram) to 4.52 (vilazodone 40 mg); men 2.83 (vilazodone 40 mg) to 6.43 (placebo)]. Across treatment groups, baseline sexual function improved in women and men, MDD responders, and patients with baseline sexual dysfunction.

Figures

Fig. 1
Fig. 1
CSFQ scores by week in women (a) and men (b). CSFQ, Changes in Sexual Functioning Questionnaire.

References

    1. American Psychiatric Association (2000). Diagnosticand Statistical Manual of Mental Disorders, text revision, 4th ed. Washington, DC: American Psychiatric Association.
    1. Angst J. (1998). Sexual problems in healthy and depressed persons. Int Clin Psychopharmacol 13 (Suppl 6):S1–S4.
    1. Ashton AK, Jamerson BD, Weinstein LW, Wagoner C. (2005). Antidepressant-related adverse effects impacting treatment compliance: results of a patient survey. Curr Ther Res Clin Exp 66:96–106.
    1. Atlantis E, Sullivan T. (2012). Bidirectional association between depression and sexual dysfunction: a systematic review and meta-analysis. J Sex Med 9:1497–1507.
    1. Bobes J, Gonzalez MP, Bascaran MT, Clayton A, Garcia M, Rico-Villade Moros F, Banús S. (2002). Evaluating changes in sexual functioning in depressed patients: sensitivity to change of the CSFQ. J Sex Marital Ther 28:93–103.
    1. Bonierbale M, Lancon C, Tignol J. (2003). The ELIXIR study: evaluation of sexual dysfunction in 4557 depressed patients in France. Curr Med Res Opin 19:114–124.
    1. Clayton AH, McGarvey EL, Clavet GJ, Piazza L. (1997). Comparison of sexual functioning in clinical and nonclinical populations using the Changes in Sexual Functioning Questionnaire (CSFQ). Psychopharmacol Bull 33:747–753.
    1. Clayton A, Kornstein S, Prakash A, Mallinckrodt C, Wohlreich M. (2007). Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder. J Sex Med 4 (Pt 1):917–929.
    1. Clayton AH, Kennedy SH, Edwards JB, Gallipoli S, Reed CR. (2013). The effect of vilazodone on sexual function during the treatment of major depressive disorder. J Sex Med 10:2465–2476.
    1. Clayton AH, Croft HA, Handiwala L. (2014). Antidepressants and sexual dysfunction: mechanisms and clinical implications. Postgrad Med 126:91–99.
    1. Giuliano F, Clement P. (2005). Physiology of ejaculation: emphasis on serotonergic control. Eur Urol 48:408–417.
    1. Hu XH, Bull SA, Hunkeler EM, Ming E, Lee JY, Fireman B, Markson LE. (2004). Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. J Clin Psychiatry 65:959–965.
    1. Kennedy SH, Rizvi S. (2009). Sexual dysfunction, depression, and the impact of antidepressants. J Clin Psychopharmacol 29:157–164.
    1. Khan A, Cutler AJ, Kajdasz DK, Gallipoli S, Athanasiou M, Robinson DS, et al. (2011). A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder. J Clin Psychiatry 72:441–447.
    1. Mathews M, Gommoll C, Chen D, Nunez R, Khan A. (2015). Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial. Int Clin Psychopharmacol 30:67–74.
    1. McGahuey CA, Gelenberg AJ, Laukes CA, Moreno FA, Delgado PL, McKnight KM, Manber R. (2000). The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther 26:25–40.
    1. Montgomery SA, Asberg M. (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382–389.
    1. Oosting RS, Olivier B, Chan J, Banerjee P. (2013). Vilazodone exhibits a favorable sexual adverse effect profile in male rats. Poster presented at the 166th Annual American Psychiatric Association Meeting; San Francisco, CA.
    1. Rickels K, Athanasiou M, Robinson DS, Gibertini M, Whalen H, Reed CR. (2009). Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 70:326–333.
    1. Robinson DS, Kajdasz DK, Gallipoli S, Whalen H, Wamil A, Reed CR. (2011). A 1-year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder. J Clin Psychopharmacol 31:643–646.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe